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 Introduction 
 Lymphoplasmacytic lymphoma (LPL)/Waldenström 
macroglobulinemia (WM) is a B-cell disorder resulting 
from the accumulation, predominantly in the bone mar-
row, of clonally related lymphoplasmacytic cells  [1, 2] . 
WM is a subset of LPL and can be distinguished clini-
cally on the basis of a monoclonal immunoglobulin M 
(IgM) protein in serum [1] . LPL/WM is a very rare dis-
ease, with an incidence rate of 3–4 cases per million peo-
ple per year [3] .
 Currently, the causes of LPL/WM are poorly under-
stood. The strongest risk factor for WM is the precursor 
condition monoclonal gammopathy of undetermined 
significance (MGUS) of the IgM class, which is associated 
with an average 1.5% annual risk of developing non-
Hodgkin lymphomas  [4] . There are emerging data to sup-
port a role for immune-related factors in the pathogenesis 
of LPL/WM [5] . In addition, data show that genetic fac-
tors are of importance in the etiology of LPL/WM. 
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 Abstract 
 Lymphoplasmacytic lymphoma (LPL)/Waldenström macro-
globulinemia (WM) is a B-cell disorder resulting from the ac-
cumulation, predominantly in the bone marrow, of clonally 
related lymphoplasmacytic cells. LPL/WM is a very rare dis-
ease, with an incidence rate of 3–4 cases per million people 
per year.  Currently, the causes of LPL/WM are poorly under-
stood; however, there are emerging data to support a role 
for immune-related factors in the pathogenesis of LPL/WM. 
In addition, data show that genetic factors are of importance 
in the etiology of LPL/WM. In this paper, we will review the 
current knowledge about familiality of LPL/WM and provide 
novel data on solid tumors and myeloid malignancies in first-
degree relatives of LPL/WM patients. 
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 Familiality and LPL/WM 
 Familial clustering in LPL and WM has been observed 
in several studies  [6–8] . In one study, including 257 WM 
patients, 19% of the patients had at least one first-degree 
relative affected with WM or another B-cell disorder, in-
cluding non-Hodgkin lymphoma, multiple myeloma, 
chronic lymphocytic leukemia, MGUS, acute lympho-
blastic leukemia, and Hodgkin lymphoma  [8] . The au-
thors also found patients with a familial history of WM 
or a plasma cell disorder to have greater bone marrow in-
volvement. In a large study from Sweden, including 2,144 
LPL/WM patients, 8,279 population-based matched con-
trols and linkable first-degree relatives of patients (n = 
6,177) and controls (n = 24,609), we found first-degree 
relatives of LPL/WM patients to have a significantly in-
creased risk of developing LPL/WM, other subtypes of 
non-Hodgkin lymphoma and MGUS, but not Hodgkin 
lymphoma or multiple myeloma, compared to first-de-
gree relatives of controls ( table  1 )  [9] . The excess risks 
were similar among parents, siblings and offspring, which 
favor the operation of dominant or codominant gene ef-
fects, rather than recessive genes. Together with previous 
studies  [10–12] , our findings support a role for shared 
common susceptibility genes that predispose to LPL/
WM and certain other lymphoproliferative disorders. 
Given the implications for future studies aimed at uncov-
ering underlying susceptibility genes, it is important to 
define the spectrum of tumors associated with LPL/WM. 
Therefore, we analyzed risks of myeloid hematological 
malignancies and solid tumors among first-degree rela-
tives of LPL/WM patients, using the database described 
above. As shown in  table 2 , first-degree relatives of LPL/
WM patients did not have an increased risk of myeloid 
malignancies [relative risk (RR) = 1.0; 95% confidence 
interval (CI) 0.6–1.7], including acute myeloid leukemia, 
myelodysplastic syndromes, chronic myeloproliferative 
neoplasms and chronic myeloid leukemia. In addition, 
first-degree relatives of LPL/WM patients had no in-
creased risk of ‘any solid tumor’ (RR = 1.08; 95% CI 0.98–
1.19). Among the 28 solid tumors tested, relatives of LPL/
WM patients had only a borderline significantly in-
creased risk of pancreas cancer (RR = 1.8; 95% CI 1.03–
3.1; p = 0.047). No significantly increased risk was found 
for any other solid tumor. Our finding of a significant 
increase in the risk of pancreas cancer has not been previ-
ously described and is of unclear significance. Due to the 
number of malignancies tested, we believe that these re-
sults can probably be explained by multiple testing and 
need to be confirmed in other series. Also, due to the in-
herent limitations of the Multigenerational Registry, we 
only have information on approximately 75% of first-de-
gree relatives. However, as the approach and complete-
ness is the same in patients and controls, the risk of bias 
is minimal. Furthermore, Altieri et al.  [13] found that a 
parental history of cancer of the stomach increased the 
familial risk of LPL; however, we did not observe an in-
creased risk of stomach cancer in our study. Our findings 
suggest that there are differences in genetic susceptibility 
to LPL/WM and to myeloid malignancies or solid tu-
mors.
 Familiality, Autoimmune Diseases and LPL/WM 
 A previous personal history of autoimmune disease 
has been shown to increase the risk of LPL/WM  [14] . Re-
cently, this has also been investigated in family members 
of LPL and WM patients. In a study including 103 WM 
patients and 272 unaffected relatives from 35 multiple-
 Table 1.  Relative risk of lymphoproliferative disorders among first-degree relatives of LPL/WM patients [9] 
Relatives of
LPL/WM patients
(n = 6,177)
Relatives of
LPL/WM controls
(n = 24,609)
Relative risk
(95% CI)
LPL/WM 10 2 20.0 (4.1–98.4)
Non-Hodgkin lymphoma 43 58  3.0 (2.0–4.4)
Chronic lymphocytic leukemia 16 19  3.4 (1.7–6.6)
Hodgkin lymphoma 4 21  0.8 (0.3–2.2)
Multiple myeloma 11 27  1.6 (0.8–3.2)
MGUS 5 4  5.0 (1.3–18.9)
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Table 2. R elative risk of solid tumors and myeloid malignancies among first-degree relatives of LPL/WM patients
Tumor site Relatives of
L PL/WM patients
(n = 6,177)
Relatives of
LPL/WM controls
(n = 24,609)
Relative risk
(95% CI)1
p
value
Myeloid malignancies 18 71 1.0 (0.6–1.7) 1.00
Acute myeloid leukemia/myelodysplastic syndromes 9 21 1.7 (0.8–3.7) 0.17
Chronic myeloproliferative neoplasm 6 38 0.6 (0.3–1.5) 0.35
Chronic myeloid leukemia 3 12 1.0 (0.3–3.5) 1.00
Any solid tumor 581 2,150 1.08 (0.98–1.19) 0.06
Buccal 6 34 0.7 (0.3–1.7) 0.55
Salivary gland 0 9 0 0.21
Esophageal 3 14 0.9 (0.2–3.0) 1.00
Stomach 18 49 1.5 (0.9–2.5) 0.17
Small intestines 4 6 2.7 (0.7–9.4) 0.12
Colon 31 129 1.0 (0.6–1.4) 0.92
Rectal 24 69 1.4 (0.9–2.2) 0.19
Liver 4 24 0.7 (0.2–1.9) 0.63
Gallbladder 3 10 1.2 (0.3–4.3) 0.73
Pancreas 18 40 1.8 (1.03–3.1) 0.047
Larynx 4 5 3.2 (0.9–11.9) 0.09
Lung 27 109 1.0 (0.6–1.5) 1.00
Renal 12 48 1.0 (0.5–1.9) 1.00
Bladder 13 72 0.7 (0.4–1.3) 0.34
Melanoma skin 41 126 1.3 (0.9–1.8) 0.15
Non-melanoma skin 36 130 1.1 (0.8–1.6) 0.62
Brain 20 59 1.4 (0.8–2.2) 0.26
Spinal cord 0 8 0 0.37
Thyroid 9 36 1.0 (0.5–2.1) 1.00
Bone 3 12 1.0 (0.3–3.5) 1.00
Connective tissue 4 14 1.1 (0.4–3.5) 0.77
Breast 86 338 1.0 (0.8–1.3) 0.85
Cervix 35 115 1.2 (0.8-1.8) 0.17
Uterus 13 80 0.7 (0.4–1.3) 0.87
Ovary 15 70 0.9 (0.5–1.5) 0.10
Vulva 2 10 0.8 (0.17–3.7) 0.72
Prostate 55 239 0.9 (0.7–1.2) 0.56
Testicular 11 28 1.6 (0.8–1.8) 0.17
1 All estimates were adjusted for sex of first-degree relative.
Details of the study population have been described previously 
[9]. In brief, Sweden provides universal medical health care for the 
entire population, which is currently approximately 9 million peo-
ple. Since 1958, all physicians, pathologists and cytologists in Swe-
den have been obliged by law to report each case of cancer they 
diagnose or treat to the centralized nationwide Swedish Cancer 
Registry.
In a validation study that focused on lymphoproliferative ma-
lignancies diagnosed from 1 January 1964 through 31 December 
2003, we found the overall complete ness and diagnostic accuracy 
of the registry to be >90%. For WM, the diagnostic accuracy was 
93%, but the com pleteness was 68% [21]. To compensate for the low 
completeness, we used parallel ap proaches to establish a nation-
wide LPL/WM cohort. First, we identified all LPL/WM patients 
who were diagnosed from 1 January 1958 through 31 December 
2005 in the nationwide Swedish Cancer Registry. Second, we re-
trieved information on patients with incident LPL/WM through 
our national network including all major hematology or oncology 
units in Sweden. Third, we identified all patients reported in the 
Swedish Inpatient Registry, which captures information on indi-
vidual patient-based dis charge diagnosis and discharge listings 
from all inpatient care, with a very high coverage. For each LPL/
WM patient, 4 population-based controls (matched by sex, year of 
birth and county of residence) were chosen randomly from the 
Swedish population database. All controls had to be alive at the 
time of LPL/WM diagnosis for the corresponding case and with no 
previous hematological malignancy at the date of the correspond-
ing case’s diagnosis. Using the Swedish Multigenerational Registry 
[22], we obtained information on all first-degree relatives (parents, 
siblings and offspring) of LPL/WM patients and controls. All LPL/
WM patients and controls without linkable relatives were removed 
from the study. As a final step, we conducted record linkages with 
the Swedish Cancer Registry and a nationwide myeloproliferative 
disorders cohort, described elsewhere [23], to obtain information 
on myeloid hematological malignancies and solid tumors among 
first-degree relatives of LPL/WM patients and controls. The statis-
tical methods have been described in detail previously [24, 25].
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case WM and 46 mixed WM/related B-cell disorder kin-
dred as well as 28 sporadic WM patients, familial WM 
patients were more likely than unaffected relatives to re-
port a history of autoimmune disease and infections  [15] . 
Familial WM patients were also more likely to report ex-
posure to farming, pesticides, wood dust and organic 
solvents compared with unaffected family members. In 
a recent study based on 2,470 LPL/WM patients, 9,698 
matched controls and almost 30,000 first-degree rela-
tives of cases and controls from Sweden, we analyzed 
whether personal or family history of a wide range of au-
toimmune, infectious, allergic, and inflammatory con-
ditions were associated with LPL/WM  [14] . A personal 
history of several autoimmune and other immune-relat-
ed disorders was associated with an increased risk of 
LPL/WM. Interestingly, a family history of Sjögren’s 
syndrome, autoimmune hemolytic anemia, Guillain-
Barré syndrome, cytomegalovirus, gingivitis and peri-
odontitis, and chronic prostatitis was associated with an 
increased risk of LPL/WM  [14] . Our findings that both 
personal and family history of Sjögren’s syndrome or au-
toimmune hemolytic anemia were associated with an in-
creased risk of LPL/WM indicate that there might be 
some shared (genetic, environmental, or both) suscepti-
bility for these conditions. Future work is needed to un-
cover the underlying mechanisms of the observed asso-
ciations. These studies provide novel information sup-
porting the application of gene mapping and candidate 
gene approaches in high-risk families and case-control 
studies. 
 Genetic Studies and LPL/WM 
 There are a number of gene candidates that could con-
tribute to a susceptibility to LPL/WM and related condi-
tions. For example, polymorphisms in lymphomagenesis, 
immune function and DNA repair genes have been found 
to be associated with an elevated risk of chronic lympho-
cytic leukemia  [16] , Hodgkin lymphoma  [17] and non-
Hodgkin lymphoma  [18] . In a genome-wide linkage anal-
ysis of 11 high-risk WM families (a total of 122 individu-
als, including 34 WM patients and 10 IgM MGUS 
patients), the strongest evidence of linkage was found on 
chromosomes 1q and 4q  [7] . Other locations suggestive of 
linkage were found on chromosomes 3 and 6. Future 
work is needed to identify gene(s) that modulate suscep-
tibility to LPL/WM. 
 Genetic Anticipation 
 Genetic anticipation refers to an earlier age at onset or 
increasing severity of a disease in successive generations. 
Trinucleotide repeat expansions explain anticipation in 
some diseases, and epigenetic changes and abnormalities 
in telomeres have also been suggested as possible mecha-
nisms that may contribute to anticipation  [19, 20] . In their 
study, Treon et al.  [8] showed that WM patients with a 
family history of WM or a plasma cell disorder were di-
agnosed at a younger age than sporadic WM cases. In our 
large population-based study, we found that offspring of 
LPL/WM patients were diagnosed with LPL/WM at an 
earlier age than the parent group. However, the age at di-
agnosis of LPL/WM was similar in offspring of controls 
and of cases, indicating that this difference is likely due 
to differences in follow-up time between generations and 
not explained by earlier diagnosis in children of parents 
with LPL/WM. This needs to be studied in more detail.
 Summary and Conclusions 
 In summary, first-degree relatives to LPL/WM pa-
tients have an increased risk of several lymphoprolifera-
tive disorders, but not other malignancies. In addition, 
there is familial aggregation of some immune-related 
conditions. These results support the hypothesis that 
there are shared susceptibility genes that predispose to 
LPL/WM and other lymphoproliferative disorders. Fu-
ture studies are needed to identify susceptibility genes 
and define the role of immune-related conditions, and 
their interaction, in the etiology of LPL/WM.
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